361 related articles for article (PubMed ID: 36614219)
1. Apoe4 and Alzheimer's Disease Pathogenesis-Mitochondrial Deregulation and Targeted Therapeutic Strategies.
Pires M; Rego AC
Int J Mol Sci; 2023 Jan; 24(1):. PubMed ID: 36614219
[No Abstract] [Full Text] [Related]
2. Roles of ApoE4 on the Pathogenesis in Alzheimer's Disease and the Potential Therapeutic Approaches.
Sun YY; Wang Z; Huang HC
Cell Mol Neurobiol; 2023 Oct; 43(7):3115-3136. PubMed ID: 37227619
[TBL] [Abstract][Full Text] [Related]
3. Apolipoprotein E, especially apolipoprotein E4, increases the oligomerization of amyloid β peptide.
Hashimoto T; Serrano-Pozo A; Hori Y; Adams KW; Takeda S; Banerji AO; Mitani A; Joyner D; Thyssen DH; Bacskai BJ; Frosch MP; Spires-Jones TL; Finn MB; Holtzman DM; Hyman BT
J Neurosci; 2012 Oct; 32(43):15181-92. PubMed ID: 23100439
[TBL] [Abstract][Full Text] [Related]
4. Molecular Basis of Alzheimer's Disease: Focus on Mitochondria.
Oliver DMA; Reddy PH
J Alzheimers Dis; 2019; 72(s1):S95-S116. PubMed ID: 30932888
[TBL] [Abstract][Full Text] [Related]
5. Transcriptional Effects of ApoE4: Relevance to Alzheimer's Disease.
Theendakara V; Peters-Libeu CA; Bredesen DE; Rao RV
Mol Neurobiol; 2018 Jun; 55(6):5243-5254. PubMed ID: 28879423
[TBL] [Abstract][Full Text] [Related]
6. APOE and Alzheimer's Disease: Evidence Mounts that Targeting APOE4 may Combat Alzheimer's Pathogenesis.
Uddin MS; Kabir MT; Al Mamun A; Abdel-Daim MM; Barreto GE; Ashraf GM
Mol Neurobiol; 2019 Apr; 56(4):2450-2465. PubMed ID: 30032423
[TBL] [Abstract][Full Text] [Related]
7. Soluble apoE/Aβ complex: mechanism and therapeutic target for APOE4-induced AD risk.
Tai LM; Mehra S; Shete V; Estus S; Rebeck GW; Bu G; LaDu MJ
Mol Neurodegener; 2014 Jan; 9():2. PubMed ID: 24386905
[TBL] [Abstract][Full Text] [Related]
8. The Effects of APOE4 on Mitochondrial Dynamics and Proteins in vivo.
Simonovitch S; Schmukler E; Masliah E; Pinkas-Kramarski R; Michaelson DM
J Alzheimers Dis; 2019; 70(3):861-875. PubMed ID: 31306119
[TBL] [Abstract][Full Text] [Related]
9. APOE4-mediated amyloid-β pathology depends on its neuronal receptor LRP1.
Tachibana M; Holm ML; Liu CC; Shinohara M; Aikawa T; Oue H; Yamazaki Y; Martens YA; Murray ME; Sullivan PM; Weyer K; Glerup S; Dickson DW; Bu G; Kanekiyo T
J Clin Invest; 2019 Mar; 129(3):1272-1277. PubMed ID: 30741718
[TBL] [Abstract][Full Text] [Related]
10. Characterizing Apolipoprotein E ε4 Carriers and Noncarriers With the Clinical Diagnosis of Mild to Moderate Alzheimer Dementia and Minimal β-Amyloid Peptide Plaques.
Monsell SE; Kukull WA; Roher AE; Maarouf CL; Serrano G; Beach TG; Caselli RJ; Montine TJ; Reiman EM
JAMA Neurol; 2015 Oct; 72(10):1124-31. PubMed ID: 26302353
[TBL] [Abstract][Full Text] [Related]
11. ApoE4 reduction: An emerging and promising therapeutic strategy for Alzheimer's disease.
Li Y; Macyczko JR; Liu CC; Bu G
Neurobiol Aging; 2022 Jul; 115():20-28. PubMed ID: 35453035
[TBL] [Abstract][Full Text] [Related]
12. Co-Expression of Glia Maturation Factor and Apolipoprotein E4 in Alzheimer's Disease Brain.
Thangavel R; Bhagavan SM; Ramaswamy SB; Surpur S; Govindarajan R; Kempuraj D; Zaheer S; Raikwar S; Ahmed ME; Selvakumar GP; Iyer SS; Zaheer A
J Alzheimers Dis; 2018; 61(2):553-560. PubMed ID: 29172001
[TBL] [Abstract][Full Text] [Related]
13. Amyloid clearance defect in ApoE4 astrocytes is reversed by epigenetic correction of endosomal pH.
Prasad H; Rao R
Proc Natl Acad Sci U S A; 2018 Jul; 115(28):E6640-E6649. PubMed ID: 29946028
[TBL] [Abstract][Full Text] [Related]
14. Imipramine and olanzapine block apoE4-catalyzed polymerization of Aβ and show evidence of improving Alzheimer's disease cognition.
Johnson NR; Wang AC; Coughlan C; Sillau S; Lucero E; Viltz L; Markham N; Allen C; Dhanasekaran AR; Chial HJ; Potter H
Alzheimers Res Ther; 2022 Jun; 14(1):88. PubMed ID: 35768831
[TBL] [Abstract][Full Text] [Related]
15. Amyloid Beta and Phosphorylated Tau-Induced Defective Autophagy and Mitophagy in Alzheimer's Disease.
Reddy PH; Oliver DM
Cells; 2019 May; 8(5):. PubMed ID: 31121890
[TBL] [Abstract][Full Text] [Related]
16. Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and Aβ metabolism in apoE4-targeted replacement mice.
Hu J; Liu CC; Chen XF; Zhang YW; Xu H; Bu G
Mol Neurodegener; 2015 Mar; 10():6. PubMed ID: 25871773
[TBL] [Abstract][Full Text] [Related]
17. Abeta, tau and ApoE4 in Alzheimer's disease: the axonal connection.
Adalbert R; Gilley J; Coleman MP
Trends Mol Med; 2007 Apr; 13(4):135-42. PubMed ID: 17344096
[TBL] [Abstract][Full Text] [Related]
18. Molecular Insight into the Therapeutic Promise of Targeting
Mamun AA; Uddin MS; Bin Bashar MF; Zaman S; Begum Y; Bulbul IJ; Islam MS; Sarwar MS; Mathew B; Amran MS; Md Ashraf G; Bin-Jumah MN; Mousa SA; Abdel-Daim MM
Oxid Med Cell Longev; 2020; 2020():5086250. PubMed ID: 32509144
[TBL] [Abstract][Full Text] [Related]
19. The Important Interface Between Apolipoprotein E and Neuroinflammation in Alzheimer's Disease.
Kloske CM; Wilcock DM
Front Immunol; 2020; 11():754. PubMed ID: 32425941
[TBL] [Abstract][Full Text] [Related]
20. Apolipoprotein E and Alzheimer's Disease: Findings, Hypotheses, and Potential Mechanisms.
Koutsodendris N; Nelson MR; Rao A; Huang Y
Annu Rev Pathol; 2022 Jan; 17():73-99. PubMed ID: 34460318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
